Iconovo AB (publ) (STO:ICO)

Market Cap	88.64M -3.3%
Revenue (ttm)	14.53M -39.5%
Net Income	-43.36M
EPS	-1.14
Shares Out	74.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,792
Average Volume	109,289
Open	1.140
Previous Close	1.150
Day's Range	1.110 - 1.220
52-Week Range	0.906 - 3.980
Beta	0.44
RSI	55.43
Earnings Date	Feb 12, 2026

About Iconovo AB

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2013
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ICO

Financial Performance

In 2025, Iconovo AB's revenue was 14.53 million, a decrease of -39.46% compared to the previous year's 24.00 million. Losses were -43.36 million, 5.41% more than in 2024.